TxCell to present at upcoming US and French investment conferences

TxCell, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces that Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015.

The presentation by TxCell at the Regen Med Investor Day will be followed by an in depth ‘fireside’ Q&A with a sell-side analyst. The meeting will be attended by a large number of institutional, strategic and venture investors with an insight into the financing hypotheses for cellular and gene therapies. The presentation is scheduled for 4.50pm, March 25 in the West Lounge Room of the Metropolitan Club, One East 60th Street, New York, US.

The Regen Med Investor Day has been organized by the Alliance for Regenerative Medicine (ARM), in partnership with leading financial firms Maxim Group and Piper Jaffray. Clinical and commercial experts will address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas such as autoimmune disease, cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by TxCell and more than 30 other leading companies from across the globe.

In the presentation, Damian Marron will provide an overview of TxCell, its personalized T cell immunotherapy platform ASTrIA, as well as an update on clinical developments and the future plans for the company. Additional details will also be provided during one on one meetings with institutional investors. Topics covered by Damian Marron include the development of Ovasave(R), TxCell’s lead product candidate in refractory Crohn’s disease, for which a multinational placebo-controlled phase IIb clinical study is ongoing, Col-Treg, TxCell’s second product candidate developed in autoimmune uveitis, a rare eye disease for which a phase I/II proof of principle clinical trial is planned to start in the first half of 2015, and TxCell’s innovative, cost-effective business model. Details of the next milestones for TxCell, including those of the EUR 76 million partnership with Ferring / Trizell will also be provided.

In addition, Portzamparc, a French brokerage and investment bank, has invited TxCell to participate at the Portzamparc PEA-PME Forum in Paris, France on April 1, 2015. The forum is organized by Portzamparc, who have selected 55 dynamic companies eligible for the PEA-PME program. TxCell will meet a number of institutional investors in one on one meetings at the Portzamparc event.

“TxCell will continue to keep members of the US and EU investment and financial communities updated and informed of TxCell developments at key global events,” said Damian Marron, CEO TxCell. “These events include the Regen Med Investor Day and the Portzamparc PEA-PME Forum. We will be able to give key investors additional information to develop investment strategies for TxCell’s advanced therapies-based treatments.”

Source: TxCell